Literature DB >> 18455525

Mannose-binding lectin haplotypes may be associated with cerebral palsy only after perinatal viral exposure.

Catherine S Gibson1, Alastair H MacLennan, Paul N Goldwater, Eric A Haan, Kevin Priest, Gustaaf A Dekker.   

Abstract

OBJECTIVE: The objective of the study was to investigate the associations between infection, polymorphisms in the mannose-binding lectin gene (MBL), and cerebral palsy (CP). STUDY
DESIGN: This was a case-control study using deoxyribonucleic acid from newborn screening cards of 443 Caucasian CP cases and 883 Caucasian controls to screen for 6 polymorphisms within the MBL gene. These polymorphisms combine to create haplotypes with high (HYPA), intermediate (LYQA, LYPA), low (LXPA), and defective (HYPD, LYQC, LYPB) circulating MBL levels.
RESULTS: chi(2) Analyses demonstrated significant differences between CP cases and controls (less than 37 weeks chi(2) 14.99, P = .02; less than 32 weeks chi(2) 13.62, P = .02). The MBL haplotype LYPA was associated with CP at all gestations (odds ratio [OR] 1.57, 95% confidence interval [CI], 1.00 to 2.46), less than 37 weeks (OR 2.43, 95% CI, 1.41 to 4.18), and less than 32 weeks (OR 2.54, 95% CI, 1.34 to 4.76). LYPA was also associated with hemiplegic CP for babies born at less than 37 weeks (OR 2.77, 95% CI, 1.02 to 7.26) and less than 32 weeks (OR 4.48, 95% CI, 1.55 to 12.65). HYPD was associated with quadriplegic CP at all gestations (OR 3.47, 95% CI, 1.41 to 8.31) as well as for babies born at less than 32 weeks (OR 7.86, 95% CI, 1.67 to 29.48). Subanalysis on samples previously testing positive for exposure to viral infection demonstrated similar patterns of significance as those presented above, whereas analysis on samples negative for exposure to viral infection showed no positive associations between any of the MBL haplotypes and CP. Potential type I error from multiple analyses is a caveat.
CONCLUSION: MBL haplotypes LYPA or HYPD may be associated with an increased risk of CP in the presence of exposure to viral infection and may act as susceptibility factors for CP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455525     DOI: 10.1016/j.ajog.2008.02.027

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Cerebral palsy and genetic predisposition.

Authors:  Athol Kent
Journal:  Rev Obstet Gynecol       Date:  2008

2.  Candidate genes and risk for CP: a population-based study.

Authors:  Yvonne W Wu; Lisa A Croen; Andrew Vanderwerf; Amy A Gelfand; Anthony R Torres
Journal:  Pediatr Res       Date:  2011-12       Impact factor: 3.756

3.  Genetic Variation, Magnesium Sulfate Exposure, and Adverse Neurodevelopmental Outcomes Following Preterm Birth.

Authors:  Erin A S Clark; Steven J Weiner; Dwight J Rouse; Brian M Mercer; Uma M Reddy; Jay D Iams; Ronald J Wapner; Yoram Sorokin; Fergal D Malone; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Donald J Dudley; Steve N Caritis
Journal:  Am J Perinatol       Date:  2018-03-06       Impact factor: 1.862

4.  Association of fetal inflammation and coagulation pathway gene polymorphisms with neurodevelopmental delay at age 2 years.

Authors:  Erin A S Clark; Lisa Mele; Ronald J Wapner; Catherine Y Spong; Yoram Sorokin; Alan Peaceman; Jay D Iams; Kenneth J Leveno; Margaret Harper; Steve N Caritis; Menachem Miodovnik; Brian M Mercer; John M Thorp; Susan M Ramin; Marshall Carpenter; Dwight J Rouse
Journal:  Am J Obstet Gynecol       Date:  2010-04-24       Impact factor: 8.661

Review 5.  The genomic basis of cerebral palsy: a HuGE systematic literature review.

Authors:  M E O'Callaghan; A H MacLennan; E A Haan; G Dekker
Journal:  Hum Genet       Date:  2009-02-24       Impact factor: 4.132

Review 6.  Factors of the lectin pathway of complement activation and their clinical associations in neonates.

Authors:  Maciej Cedzynski; Anna St Swierzko; David C Kilpatrick
Journal:  J Biomed Biotechnol       Date:  2012-03-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.